WEST Search History

Hide liems | Restore | Clear | Cancel

DATE: Wednesday, July 26, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB,	USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=Y	ES; OP=ADJ
	L6	mucociliary clearance and bikunin	7
	L5	mucociliary clearence and bikunin	0
	L4	L1 and bikunin	2
	L3	L1 and Kunitz	1
	L2	L1 and Kunitz and serine protease inhibitor	1
	L1	chronic obstructive lung disease	753

END OF SEARCH HISTORY

Hit List

First Hit Clear Cenerale Collection Print Fwd Refs Elwd Refs

Generate OACS

Search Results - Record(s) 1 through 7 of 7 returned.

☐ 1. Document ID: US 20050222023 A1

L6: Entry 1 of 7 File: PGPB

Oct 6, 2005

Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20050222023

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050222023 A1

TITLE: Albumin-fused kunitz domain peptides

PUBLICATION-DATE: October 6, 2005

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY Hauser, Hans-Peter DE Marburg PA Weimer, Thomas Gladenbach IL DE Parkerford MD US Romberg, Val Bourbonnais US Kee, Scott M. MA Sleep, Darrell Nottingham GB Ladner, Robert Charles Ijamsville US Newton US Ley, Arthur C.

US-CL-CURRENT: <u>514/12</u>; <u>530/363</u>

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw, De
	_	Ъ	III	110.00	040171704	A 1						
J	2.	Docume	nt ID:	US 20	040171794	ΑI						

File: PGPB

PGPUB-DOCUMENT-NUMBER: 20040171794

PGPUB-FILING-TYPE: new

L6: Entry 2 of 7

DOCUMENT-IDENTIFIER: US 20040171794 A1

TITLE: Kunitz domain peptides

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY
Ladner, Robert Charles Ijamsville MD US
Ley, Arthur C. Newton MA US

Record List Display Page 2 of 6

US-CL-CURRENT: 530/324

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw. De

☐ 3. Document ID: US 20040167184 A1

L6: Entry 3 of 7

File: PGPB

Aug 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040167184

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040167184 A1

TITLE: Treatment of lung cells with histone deacetylase inhibitors

PUBLICATION-DATE: August 26, 2004

INVENTOR-INFORMATION:

NAME CITY STATE COUNTRY

Wiech, Norbert L. Phoenix MD US Lan-Hargest, Hsuan-Yin Fallston MD US

US-CL-CURRENT: <u>514/357</u>; <u>514/408</u>, <u>514/430</u>, <u>514/471</u>

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KMC Draw, De

☐ 4. Document ID: US 7019123 B2

L6: Entry 4 of 7 File: USPT Mar 28, 2006

US-PAT-NO: 7019123

DOCUMENT-IDENTIFIER: US 7019123 B2

TITLE: Human bikunin

DATE-ISSUED: March 28, 2006

PRIOR-PUBLICATION:

DOC-ID DATE

US 20030194398 A1 October 16, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY Tamburini; Paul P. Kensington CTUS Davis; Gary Milford CTUS Delaria; Katherine A. West Haven CT US Marlor; Christopher W. Bethany CTUS Muller; Daniel K. Orange CTUS

US-CL-CURRENT: 536/23.1; 435/195, 435/320.1, 435/440, 435/69.1

ABSTRACT:

The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental <u>bikunin</u>, serine protease inhibitor domains, and fragments thereof

6 Claims, 24 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 41

Full	Title	Citation Front	Review	Classification	Date	Reference	Sequences	Altachments	Claims	KMC	Draw. De
			····· <u>-</u> ···								
	5.	Document ID:	US 69	89369 B2							

File: USPT

US-PAT-NO: 6989369

L6: Entry 5 of 7

DOCUMENT-IDENTIFIER: US 6989369 B2

TITLE: Kunitz domain peptides

DATE-ISSUED: January 24, 2006

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20040171794 A1

September 2, 2004

INVENTOR-INFORMATION:

NAME

CITY

STATE

ZIP CODE

COUNTRY

Jan 24, 2006

Ladner; Robert Charles

Ijamsville

MD

US

Ley; Arthur C.

Newton

MA

US

US-CL-CURRENT: 514/12; 530/324

ABSTRACT:

The invention relates to a Kunitz domain peptide, designated DPI-14 herein, for inhibiting human neutrophil elastase. The invention also relates to a method of using a DPI-14 for treating cystic fibrosis or cystic fibrosis-related disease or disorder.

27 Claims, 6 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw, De
							_					

☐ 6. Document ID: US 6583108 B1

Record List Display Page 4 of 6

L6: Entry 6 of 7 File: USPT Jun 24, 2003

US-PAT-NO: 6583108

DOCUMENT-IDENTIFIER: US 6583108 B1

** See image for Certificate of Correction **

TITLE: Human bikunin

DATE-ISSUED: June 24, 2003

INVENTOR - INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Tamburini; Paul P. Kensington CT
Davis; Gary Milford CT
Delaria; Katherine A. West Haven CT
Marlor; Christopher W. Bethany CT
Muller; Daniel K. Orange CT

US-CL-CURRENT: 514/2; 435/69.2, 514/12, 514/8, 530/324, 530/350, 530/395, 536/23.5

ABSTRACT:

The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental <u>bikunin</u>, serine protease inhibitor domains, and fragments thereof.

9 Claims, 42 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 41

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	K000C	Draws De
							22					

☐ 7. Document ID: MX 230915 B, WO 200037099 A2, AU 200019878 A, EP 1140150 A2, CN 1334743 A, JP 2002532558 W, AU 758832 B, MX 2001006510 A1, EP 1140150 B1, DE 69912988 E, EP 1374891 A1, ES 2209542 T3

L6: Entry 7 of 7

File: DWPI

Sep 29, 2005

DERWENT-ACC-NO: 2000-452127

DERWENT-WEEK: 200617

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Stimulating <u>mucociliary clearance</u> rate of mucus and sputum in lung airways for treating lung diseases such as cystic fibrosis and bronchitis involves administering a Kunitz-type serine protease inhibitor

INVENTOR: HALL, R; NEWTON, B B; POLL, C T; TAYLOR, W J A; HALL, R L

PRIORITY-DATA: 1999US-0441966 (November 17, 1999), 1998US-0218913 (December 22, 1998)

PΔ	TE	ИТ∽	FΑ	мт	LY	٠

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
MX 230915 B	September 29, 2005		000	A61K038/57
WO 200037099 A2	June 29, 2000	E	173	A61K038/57
AU 200019878 A	July 12, 2000		000	A61K038/57
EP 1140150 A2	October 10, 2001	E	000	A61K038/57
CN 1334743 A	February 6, 2002		000	A61K038/57
JP 2002532558 W	October 2, 2002		227	A61K038/55
AU 758832 B	April 3, 2003		000	A61K038/57
MX 2001006510 A1	January 1, 2002		000	A61K038/57
EP 1140150 B1	November 19, 2003	E	000	A61K038/57
DE 69912988 E	December 24, 2003		000	A61K038/57
EP 1374891 A1	January 2, 2004	E	000	A61K038/57
ES 2209542 T3	June 16, 2004		000	A61K038/57

INT-CL (IPC): A61 K 9/12; A61 K 9/72; A61 K 38/55; A61 K 38/57; A61 K 47/02; A61 P 11/00; A61 P 11/02; A61 P 11/06; A61 P 11/12; A61 P 27/16; A61 P 43/00; C07 K 14/81

ABSTRACTED-PUB-NO: WO 200037099A

BASIC-ABSTRACT:

NOVELTY - Accelerating the rate of mucociliary clearance in a subject comprising administering a composition (I) comprising a Kunitz-type serine protease inhibitor (KSPI).

ACTIVITY - Antiinflammatory. The effect of the Kunitz family serine protease inhibitor, bikunin, was studied on sheep tracheal mucus velocity (TMV) over 8 hours after treatment with bikunin. 9 mg bikunin (3 ml of 3 mg/ml) was administrated by a nebulized aerosol to the airways and to measure TMV, 5-10 radiopaque Teflon (RTM) particles were insufflated into the trachea via a catheter placed within the endotracheal tube. The movement of the Teflon (RTM) particles was then measured for 1 minute. TMV was calculated from the average distance in a cephalad direction traveled per minute for 5 - 10 Teflon particles. Baseline TMV was measured immediately prior to administration of the aerosol for 8 hours with an interval of 1 hour. The results showed that bikunin aerosol delivered to sheep airways significantly increased TMV at 8 hours compared to the same time for a group of animals receiving phosphate buffered saline (PBS) vehicle aerosol.

MECHANISM OF ACTION - Serine protease inhibitor.

USE - Kunitz-type serine protease inhibitors are useful for stimulating the rate of mucociliary clearance of mucus and sputum in the lung airways (claimed). The inhibitors are useful for treating lung diseases such as cystic fibrosis, chronic bronchitis, bronchiectasis and chronic sinusitis and glue ear caused by retention and accumulation of mucus.

ADVANTAGE - The composition reduces or eliminates mucus and sputum in lung airways in patients with chronic obstructive lung disease and reduces the risk of secondary lung infections and other adverse side effects, as well as avoiding or delaying the need for lung transplant surgery in cystic fibrosis patients. Inhibitors are human proteins and therefore reduce the risk of kidney damage on administration of large doses of Trasylol proteins.

Full Title Citation Front Review Classification Date Reference Seq.3FCP3 Attachments Claims Kill Draw, De

er Cenerale Collection : Print: Fwe Refs	Bland Refs Generate OACS
Terms	Documents
mucociliary clearance and bikunin	7

Display Format: -Change Format

Previous Page Next Page Go to Doc#